This manuscript evaluated the impact of demand- and supply-side policies on biosimilar market penetration and identified effective strategies for promoting biosimilar uptake in eight high-income countries.
#biosimilars#marketpenetration#OpenAccess
https://t.co/Gw5R1BmpeB
This study evaluated quality attributes of multiple lots of reference products and their biosimilars approved in Japan.
#biosimilars#qualityattributes#openaccess
https://t.co/pcOstPKJDi
This review presents current and future treatment options for Fabry disease, with advantages and disadvantages of the different treatment options.
#FabryDisease#genetherapy#OpenAccess
https://t.co/nWtcFbs5J2
This study investigates the structural origins and functional implications of charge heterogeneity in two therapeutic IgG2 antibodies using free-flow isoelectric focusing (FF-IEF).
#chargevariants#monoclonalantibodies#isoelectricfocusing
https://t.co/zlsnJqX5tC
This narrative review provides insights into the efficacy and safety of transitioning to and among adalimumab biosimilars in adult patients from clinical studies and real-world evidence from outside the USA.
#biosimilars#adalilumab#realworldevidence
https://t.co/0HsNsKxQpT
This review summarizes the recent advances in the knowledge of IgM biogenesis and structure and discusses the therapeutic opportunities of IgM over IgG and outstanding challenges.
#antibody#immunoglobulinM#monoclonalAntibodies
https://t.co/CCdc18sRda
This study provides real-world evidence on the effectiveness and safety of spesolimab treatment for GPP flares, based on a case series of Portuguese patients.
#GeneralizedPustularPsoriasis#spesolimab#il36
https://t.co/iD6B00xwRu
This article highlights the evolution of nucleic acid-based drug development, focusing on the pioneering agents fomivirsen, patisiran, & givosiran, & discusses the ongoing challenges in advancing these therapeutics & vaccines
#nucleicaciddrugs#genetherapy
https://t.co/F4GqO23S2q
CM326 is a novel monoclonal antibody targeting TSLP under investigation for the treatment of several type 2 inflammatory diseases. This study presents preclinical characterization and phase I human trials.
#thymicstromallymphopoietin#inflammatorydisease
https://t.co/oMKRFP59bU
In this cohort study of older patients with immune-mediated inflammatory diseases, Gianluca Trifirรฒ et al found a 6-fold increase in use of biologics from 2010 to 2022, and a treatment persistence of ~50% at one year.
#OpenAccess#biologics#olderadults
https://t.co/LIKSbUrMVW
This study investigated the clinical safety, tolerability, pharmacokinetics & preliminary pharmacodynamics of HEC88473, a 2nd generation GLP-1/FGF21 agonist, in a phase I, single-ascending dose trial with healthy & obese subjects
#glp1#FGF21#FirstInHuman
https://t.co/rE8DlJi4mi
Torleif Tollefsrud Gjรธlberg and colleagues describe FcRn biology, and give an overview of the current clinical pipeline of FcRn antagonists in autoimmune diseases.
#neonatalFcReceptor#autoimmunedisease#OpenAccess
https://t.co/SvOaWbuBVs
This review explores the basic structure, preclinical principles, clinical trial progress, and challenges of multispecific antibodies targeting PD-1/PD-L1 in tumor therapy.
#multispecificantibodies#BispecificAntibodies#CancerImmunotherapy
https://t.co/2mTd8KbsIy
Structure activity relationship studies of the biosimilar BAT1806/BIIB800 and reference tocilizumab were conducted to assess the potential impact of observed minor differences in quality attributes
#biosimilarity#Structureactivity#Tocilizumab#openaccess
https://t.co/G17OZww26V
Findings from a targeted review have been incorporated into a framework of biosimilar market sustainability dimensions, to be used by stakeholders in decision-making to ensure long-term viability of the market.
#Biosimilar#biosimilarmarket#sustainability
https://t.co/XhZyXbzwWh
This analysis reviewed biosimilar-promoting policies in 13 OECD countries and examined their impact on biosimilar uptake and expenditure reduction for adalimumab, etanercept, and infliximab.
#biosimilar#tendering#HealthcarePolicy#healthcarecosts
https://t.co/qBDxDM4BWB
This review highlights the importance of biosimilars of reference eculizumab and their entry for use in patients with paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome.
#Biosimilar#eculizumab#openaccess
https://t.co/xZMkgvttVB
Alfredo Addeo & colleagues review proposed mechanisms of resistance to immunotherapy with checkpoint inhibitors, & discuss therapeutic strategies designed to prevent primary resistance and counteract acquired resistance.
#immunotherapy#NSCLC#OpenAccess https://t.co/qo1MjjnDSB
Arthur Rech Tondin & Giacomo Lanzoni provide an overview of current islet replacement strategies for type 1 diabetes, ranging from islet transplantation to stem cell-derived islet cell transplantation.
#diabetes#isletcell#celltherapy#OpenAccess
https://t.co/XtCycRzc4O